Frontlight ResearchEarly access
Active, not recruitingPhase 2
Assessing a Clinically-meaningful Opioid Withdrawal Phenotype
Key facts
- Who runs it
- University of Maryland, Baltimore
- Where
- Baltimore, United StatesSee the site
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2
- People taking part
- 60 people, planned
- Started
- 1 Dec 2021
- Expected to end
- 28 Feb 2027
- Type of study
- Interventional
- Treatments tested
- Hydromorphone
- Naloxone + lofexidine pretreatment
- Naloxone + placebo pretreatment
- Lofexidine
- Record updated
- 12 November 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- 18 years - 65 year old
- Opioid-positive urine sample
- Current opioid use disorder with evidence of physical dependence
- Interest in undergoing opioid taper
Who cannot take part
- History of myocardial infarction
- Subjects who are positive for hepatitis B surface antigen and/or hepatitis C antibody with liver function tests outside the normal range (persons with a positive hepatitis C antibody and normal liver functions tests are NOT excluded from the study)
- Significant mental health or physical disorder, or life circumstances, that is expected to interfere with study participation
- Evidence of physical dependence on alcohol or benzodiazepines that requires medical intervention
- Being pregnant or breastfeeding
- Enrolled in methadone or buprenorphine maintenance treatment
- Clinically significant hypotension (<90/60mmHg) or bradycardia (<45bpm)
Where in United States
- University of MarylandBaltimore, United States
About the trial
What the trial wants to find out
Evaluate individual differences in the expression of opioid withdrawal symptoms in persons with opioid use disorder (OUD) while completing a clinically-indicated medication taper.
The group in the trial
- Within-subject designOther group
All participants will undergo the same study design, which includes hydromorphone stabilization (days 1-5), two naloxone challenges (scheduled during morphine stabilization), lofexidine-assisted taper (days 6-10), and transition to aftercare (day 11).
Treatment: Hydromorphone, Naloxone + lofexidine pretreatment, Naloxone + placebo pretreatment, and Lofexidine
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 12 November 2026